Synthesis, biological evaluation and molecular modelling insights of 2-arylquinazoline benzamide derivatives as anti-tubercular agents

Design, synthesis, crystal structure, fungicidal activity, and mechanism of action of novel thiazole-based hydrazide derivatives containing the 4-aminoquinazoline moiety

A family of novel thiazole-based hydrazide derivatives bearing the 4-aminoquinazoline moiety were designed and synthesized by the molecular hybridization strategy, and assessed for their antifungal activities in vitro and in vivo. Among these derivatives, the chemical structure of compound A26 was clearly confirmed via X-ray crystallography. The bioassay results revealed that some of the synthesized compounds exhibited significant inhibition effects against the tested phytopathogenic fungi. For example, in vitro EC50 (half maximal effective concentration) values of compounds A19 and A26 against Rhizoctonia solani, A19 against Verticillium dahliae, A26 against Alternaria solani, and A17 against Colletotrichum gloeosporioides were all less than 3.0 μg/mL. In particular, compound A19 with a 2-fluorophenyl group had an EC50 value as low as 2.87 μg/mL towards R. solani, comparable to that of Chlorothalonil (1.44 μg/mL) and slightly inferior to those of Carbendazim and Boscalid (0.85 and 0.83 μg/mL, respectively). In addition, in vivo assays using this compound displayed the curative and protective efficiencies of 48.4% and 59.6% against R. solani, respectively, at the concentration of 200 μg/mL. Moreover, the mechanistic studies indicated that compound A19 likely exerted its highly antifungal effects by acting as an effective succinate dehydrogenase (SDH) inhibitor with an IC50 value of 29.33 μM, based on SDH enzymatic inhibition assays and molecular docking studies. Meanwhile, the presence of compound A19 adversely impacted the integrity of cell membranes and mycelial morphologies of R. solani.

Discovery of New Benzohydrazide Derivatives Containing 4-Aminoquinazoline as Effective Agricultural Fungicides, the Related Mechanistic Study, and Safety Assessment

A total of 38 new benzohydrazide derivatives bearing the 4-aminoquinazoline moiety were designed and synthesized based on the active subunit combination approach and tested in detail for their inhibition activities against eight agricultural phytopathogenic fungi. The bioassay results indicated that many of the synthesized compounds exhibited extraordinary fungicidal activities in vitro against the tested fungi. For example, compounds A5, A6, A11, and A17 had EC50 (half-maximal effective concentration) values of 0.66, 0.71, 0.40, and 0.42 μg/mL against Colletotrichum gloeosporioides, respectively, comparable to that of boscalid (0.36 μg/mL) and much superior to that of carbendazim (6.96 μg/mL). Of particular importance was that compound A6 with a 3,4-difluorophenyl group was found to possess good broad-spectrum antifungal effects, with EC50 values ranging from 0.63 to 3.82 μg/mL against the tested eight fungi. In vivo antifungal assays also revealed that compound A6 had good curative and protective efficacies of 72.6% and 78.9% at 200 μg/mL against Rhizoctonia solani-caused rice sheath blight, higher than those of boscalid (70.7 and 65.2%, respectively). Moreover, the mechanism-of-action studies revealed that compound A6 disrupted the cell membrane integrity of R. solani, as proved by relative conductivity measurements, leakage of cellular contents, fluorescence microscopy, and scanning electron microscopy observations. Significantly, this compound also exhibited an effective inhibition of succinate dehydrogenase (SDH) from R. solani (half-maximal inhibitory concentration/IC50 = 11.02 μM), slightly weaker than that of the SDH inhibitor boscalid (5.17 μM). Further molecular docking analysis revealed that compound A6 could form strong interactions with the key residues of SDH enzyme via hydrogen bond, electrostatic, and π-cation interactions, holding promise for acting as new fungicide leads targeting SDH. Finally, the safety assessments indicated that compound A6 was safe for rice and honeybees.

Novel Para-Aminobenzoic Acid Analogs and Their Potential Therapeutic Applications

A "building block" is a key component that plays a substantial and critical function in the pharmaceutical research and development industry. Given its structural versatility and ability to undergo substitutions at both the amino and carboxyl groups, para-aminobenzoic acid (PABA) is a commonly used building block in pharmaceuticals. Therefore, it is great for the development of a wide range of novel molecules with potential medical applications. Anticancer, anti-Alzheimer's, antibacterial, antiviral, antioxidant, and anti-inflammatory properties have been observed in PABA compounds, suggesting their potential as therapeutic agents in future clinical trials. PABA-based therapeutic chemicals as molecular targets and their usage in biological processes are the primary focus of this review study. PABA's unique features make it a strong candidate for inclusion in a massive chemical database of molecules having drug-like effects. Based on the current literature, further investigation is needed to evaluate the safety and efficacy of PABA derivatives in clinical investigations and better understand the specific mechanism of action revealed by these compounds.

Antimicrobial, anticancer and immunomodulatory potential of new quinazolines bearing benzenesulfonamide moiety

Sulfonamides are privileged candidates with potent anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and could replenish the MRSA antibiotic pipeline. The initial screening of a series of quinazolinone benzenesulfonamide derivatives 5-18 against multidrug-resistant bacterial and fungal strains revealed their potent activity. The promising compounds were conjugated with ZnONPs to study the effect of nanoparticle formation on the antimicrobial, cytotoxic and immunomodulatory activity. Compounds 5, 11, 16 and 18 revealed promising antimicrobial and cytotoxic activities with superior safety profiles and enhanced activity upon nanoformulation. The immunomodulatory potential of compounds 5, 11, 16 and 18 was assessed. Compounds 5 and 11 demonstrated an increase in spleen and thymus weight and boosted the activation of CD4⁺ and CD8⁺ T lymphocytes, confirming their promising antimicrobial, cytotoxic and immunomodulatory activity.

Synthesis, X-ray Structure, Hirshfeld, DFT and Biological Studies on a Quinazolinone-Nitrate Complex

The reaction of 4-hydroxyquinazoline (4HQZ) with aqueous solution of nitric acid afforded the corresponding quinazolinone-nitrate (4HQZN) complex in very good yield. The crystal structure of 4HQZN was determined and its structural and supramolecular structural aspects were analyzed. 4HQZN crystallized in the space group P21/c and monoclinic crystal system with one [4HQZ-H]+[NO3]- formula and Z = 4. Its supramolecular structure could be described as a 2D infinite layers in which the 4HQZN molecules are connected via N-H…O and C-H…O hydrogen bridges. Using DFT calculations, the relative stability of five suggested isomers of 4HQZN were predicted. It was found that the medium effects have strong impact not only on the isomers' stability but also on the structure of the 4HQZN. It was found that the structure of 4HQZN in DMSO and methanol matched well with the reported X-ray structure which shed the light on the importance of the intermolecular interactions on the isomers' stability. The structure of 4HQZN could be described as a proton transfer complex in which the nitrate anion acting as an e-donor whiles the protonated 4HQZ is an e-acceptor. In contrast, the structure of the isolated 4HQZN in gas phase and in cyclohexane could be described as a 4HQZ…HNO3 hydrogen bonded complex. Biological screening of the antioxidant, anticancer and antimicrobial activities of 4HQZ and 4HQZN was presented and compared. It was found that, 4HQZN has higher antioxidant activity (IC50 = 36.59 ± 1.23 µg/mL) than 4HQZ. Both of 4HQZ and 4HQZN showed cell growth inhibition against breast (MCF-7) and lung (A-549) carcinoma cell lines with different extents. The 4HQZ has better activity with IC50 of 178.08 ± 6.24 µg/mL and 119.84 ± 4.98 µg/mL, respectively. The corresponding values for 4HQZN are 249.87 ± 9.71 µg/mL and 237.02 ± 8.64 µg/mL, respectively. Also, the antibacterial and antifungal activities of 4HQZN are higher than 4HQZ against all studied microbes. The most promising result is for 4HQZN against A. fumigatus (MIC = 312.5 μg/mL).

Copper mediated one-pot synthesis of quinazolinones and exploration of piperazine linked quinazoline derivatives as anti-mycobacterial agents

A facile method was developed for the synthesis of quinazolinone derivatives in a one-pot condensation reaction via in situ amine generation using ammonia as the amine source and with the formation of four new C-N bonds in good to excellent yields. With the optimised method, we synthesized a library of piperazine linked quinazoline derivatives and the synthesized compounds were evaluated for their inhibitory activity against Mycobacterium tuberculosis. The compounds 8b, 8e, 8f, 8m, 8n and 8v showed potent anti-mycobacterial activity with MIC values of 2-16 μg mL-1. All the synthesized compounds follow Lipinski's rules for drug likeness.

Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis

Owing to the rapid rise in antibiotic resistance, infectious diseases have become serious threat to public health. There is an urgent need to develop new antimicrobial agents with diverse chemical structures and novel mechanisms of action to overcome the resistance. In recent years, Quinazoline-benzimidazole hybrids have emerged as a new class of antimicrobial agents active against S. aureus and M. tuberculosis. In the current study, we designed and synthesized fifteen new Quinazoline-benzimidazole hybrids and evaluated them for their antimicrobial activity against S. aureus ATCC 29213 and M. tuberculosis H37Rv. These studies led to the identification of nine potent antibacterial agents 8a, 8b, 8c, 8d, 8f, 8g, 8h, 8i and 10c with MICs in the range of 4-64 μg/mL. Further, these selected compounds were found to possess potent antibacterial potential against a panel of drug-resistant clinical isolates which include methicillin and vancomycin-resistant S. aureus. The selected compounds were found to be less toxic to Vero cells (CC₅₀ = 40-≥200 μg/mL) and demonstrated a favourable selectivity index. Based on the encouraging results obtained these new benzimidazol-2-yl quinazoline derivatives have emerged as promising antimicrobial agents for the treatment of MDR- S. aureus and Mycobacterial infections.